A
Andrew McMillan
Researcher at Nottingham University Hospitals NHS Trust
Publications - 119
Citations - 6194
Andrew McMillan is an academic researcher from Nottingham University Hospitals NHS Trust. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Rituximab. The author has an hindex of 28, co-authored 104 publications receiving 4957 citations. Previous affiliations of Andrew McMillan include University of Nottingham & Nottingham City Hospital.
Papers
More filters
Journal ArticleDOI
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding,Susan M. Richards,Rajesh Chopra,Hillard M. Lazarus,Mark R. Litzow,Georgina Buck,I. Jill Durrant,Selina M. Luger,David I. Marks,Ian M. Franklin,Andrew McMillan,Martin S. Tallman,Jacob M. Rowe,Anthony H. Goldstone +13 more
TL;DR: It is concluded from a large, unselected series with mature follow-up that most adults with recurring ALL cannot be rescued using currently available therapies and prevention of recurrence is the best strategy for long-term survival in this disease.
Journal ArticleDOI
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Anthony H. Goldstone,Susan M. Richards,H M Lazarus,Martin S. Tallman,Georgina Buck,Adele K. Fielding,Alan Kenneth Burnett,R Chopra,Peter H. Wiernik,Letizia Foroni,Elizabeth Paietta,Mark R. Litzow,David I. Marks,Jill Durrant,Andrew McMillan,Ian M. Franklin,Selina M. Luger,Niculae Ciobanu,Jacob M. Rowe +18 more
TL;DR: Matched related allogeneic transplantations for ALL in first complete remission provide the most potent antileukemic therapy and considerable survival benefit for standard-risk patients, but the transplantation-related mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse risk.
Journal ArticleDOI
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford,Timothy M Illidge,Nicholas Counsell,Barry W. Hancock,R. Pettengell,Peter Johnson,Jennie Z Wimperis,Dominic Culligan,Bilyana Popova,Paul Smith,Andrew McMillan,Alison Brownell,Anton Kruger,Andrew Lister,Peter Hoskin,Michael O'Doherty,Sally F. Barrington +16 more
TL;DR: Patients with early-stage Hodgkin's lymphoma and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation radiotherapy, and the noninferiority of the strategy of no further treatment after chemotherapy with regard to progression-free survival did not show.
Journal ArticleDOI
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
David Cunningham,Eliza A Hawkes,Andrew Jack,Wendi Qian,Paul Smith,Paul R Mouncey,Christopher Pocock,Kirit M. Ardeshna,Kirit M. Ardeshna,John Radford,Andrew McMillan,John Davies,Deborah Turner,Anton Kruger,Peter Johnson,Joanna Gambell,David C. Linch +16 more
TL;DR: No significant improvement was noted in 2-year progression-free survival and high international prognostic index, poor-prognosis molecular characteristics, and cell of origin were not predictive for benefit from either schedule.
Journal ArticleDOI
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn,Alex F. Herrera,Christopher R. Flowers,Manali Kamdar,Andrew McMillan,Mark Hertzberg,Sarit Assouline,Tae Min Kim,Won Seog Kim,Muhit Ozcan,Jamie Hirata,Elicia Penuel,Joseph N. Paulson,Ji Cheng,Grace Ku,Matthew J. Matasar +15 more
TL;DR: Polatuzumab vedotin combined with BR resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.